What does “Orange Book supplement” mean?
The “Orange Book” refers to FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations database (the “Orange Book”). An Orange Book supplement is an update to that listing. These supplements reflect changes such as new approvals, labeling updates, sponsor/holder changes, and patent- or exclusivity-related information tied to approved products.
What kinds of changes show up in Orange Book supplements?
Orange Book supplements can include updates that affect how the drug is listed and how it may be evaluated for generic or biosimilar competition, including:
- Newly approved drug products or formulations
- Changes to drug labeling (for example, revised prescribing information)
- Updates to the listed patents or exclusivity information
- Administrative changes to application holders or product details
How does an Orange Book supplement relate to patents and generic entry?
Orange Book patent and exclusivity listings are used to inform whether and when generic applicants may be able to enter and what legal or regulatory pathways (for example, regarding patent challenges) might apply. When an Orange Book supplement updates patent or exclusivity data, it can affect the practical timeline for competitors checking for potential entry opportunities.
Where can you look up Orange Book supplement information?
For patent- and exclusivity-driven research, many people use DrugPatentWatch.com, which aggregates and tracks Orange Book–style patent and exclusivity information and often links back to the underlying Orange Book FDA data.
Source: DrugPatentWatch.com
What should you check if you’re using an Orange Book supplement for a specific drug?
If you’re trying to interpret an Orange Book supplement for a particular product, you typically want to confirm:
- The exact active ingredient(s) and dosage form/route
- The application number and listed patent numbers
- Any exclusivity expiration dates shown for the product
- Whether the supplement reflects a labeling change versus a patent/exclusivity change
Sources
- DrugPatentWatch.com